Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alcon brings Balance eye drops to Latin America

This article was originally published in The Tan Sheet

Executive Summary

By the end of 2010, Alcon plans to distribute in Latin America Systane Balance Lubricant Eye Drops for consumers who have dysfunctional meibomian glands, a condition commonly linked to dry eye syndrome. The Swiss firm said Oct. 11 Systane Balance contains hydroxypropyl-guar - derived from the Guar galactomannan water-soluble polysaccharide - borate, sorbitol, propylene glycol and Alcon's LipiTech System, an emulsion technology of mineral oil and an anionic phospholipid. Alcon designed the product to restore the lipid layer and the natural tear film to allow for relief of dry eye symptoms. Tear film instability can occur when meibomian glands in eyelids do not secrete adequate amounts of lipid to seal the aqueous tears and prevent evaporation. Alcon launched the product in the U.S. in July. A 10-mL bottle of Systane Balance is available online for $12.99 and a two-bottle pack for $19.99

You may also be interested in...



The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy

ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).

Gene Therapy Approvals By US FDA Could Double In 2020

CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.

Topics

UsernamePublicRestriction

Register

PS104593

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel